Such an agent might be also helpful in identifying tumors that arc resistant to cyclophosphomide chemotherapy because ALDH1 is known to be responsible for this resistance.
Methods: We developed schemes for the synthesis of two radioiodinated aldehdyes – N-formylmethyl-5-[*I]iodopyridine-3-carboxamide
([*I]FMIC) and 4-diethylamino-3-[*I]iodobenzaldehyde ([*I]DEIBA)-at no-canier-added levels from their respective tin precursors. These agents were evaluated using pure ALDH1 and tumor cells that expressed the enzyme.
Results: The average radiochemical yields for the synthesis of [(125)I]FMIC and [(125)I]DEIBA were 70 +/- 5% and 47 +/- 14%, respectively. ALDH1 converted both compounds to respective acids suggesting click here their suitability as ALDH1 imaging agents. Although ability buy LY3009104 of ALDH1 within the cells to oxidize one of these substrates was shown, specific uptake in ALDH-expressing tumor cells Could not be demonstrated.
Conclusion: To pursue this approach for ALDH1 imaging, radiolabeled aldehydes need to be designed such that, in addition to being good substrates for ALDH1, the cognate products should be sufficiently polar so as to be retained within the cells. (C) 2009 Elsevier Inc. All
rights reserved.”
“Purpose: We determined the efficacy of coenzyme Q10 supplementation on semen parameters, sperm function and reproductive hormone profiles in infertile men.
Materials and Methods: A total of 212 infertile men with idiopathic oligo-asthenoteratospermia were randomly assigned to receive 300 mg coenzyme Q10 (Kaneka, Osaka, Japan) orally daily (106 in group 1) or a similar placebo regimen (106 in group 2) during a 26-week period, followed by a 30-week treatment-free phase. Two semen analyses, acrosome reaction test, immunobead test for antisperm antibody, and determination of resting levels of luteinizing hormone, follicle-stimulating hormone, prolactin, testosterone and
inhibin B were done in all participants. Blood and seminal plasma total coenzyme Q10 was also assessed.
Results: Significant improvement in sperm density and see more motility was evident with coenzyme Q10 therapy (each p = 0.01). Using the Kruger classification sperm morphology evaluation revealed an increase in the percent of normal forms in the coenzyme Q10 group (p = 0.07). A positive correlation was found between treatment duration with coenzyme Q10 and sperm count (r = 0.46, p = 0.03) as well as with sperm motility (r = 0.45, p = 0.04) and sperm morphology (r = 0.34, p = 0.04). The coenzyme Q10 group had a significant decrease in serum follicle-stimulating hormone and luteinizing hormone at the 26-week treatment phase (each p = 0.03). By the end of the treatment phase the mean +/- SD acrosome reaction had increased from 14% +/- 8% and 15% +/- 8% to 31% +/- 11% and 16% +/- 10% in the coenzyme Q10 and placebo groups, respectively (p = 0.01).